Клиническое руководство по ведению больныхс инфекциями нижних отделов дыхательных путей

1. ERS Task Force Report. Guidelines for management of adult communityacquired lower respiratory tract infections. European Respiratory Society. Eur Respir J 1998;11: 986-991.

2. Davie A.P., Francis C.M., Caruana L., Sutherland G.R., McMurray J.J. Assessing diagnosis in heart failure: which features are any use? Q. J. Med. 1997; 90: 335-339.

3. Cost B., Grobbee D.E., Mostert A., Hoes A.W. Detection of heart failure in elderly in general practice. Erasmus University, Amsterdam, Netherlands, 2000.

4. Wells P.S., Anderson D.R., Rodger M. et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and ddimer. Ann. Intern. Med. 2001;135: 98-107.

5. Thiadens H.A., de Bock G.H., Dekker F.W. et al. Identifying asthma and chronic obstructive pulmonary disease in patients with persistent cough presenting to general practitioners: descriptive study. BMJ 1998; 316: 1286-1290.

6. Hallett J.S., Jacobs R.L. Recurrent acute bronchitis: the association with undiagnosed bronchial asthma. Ann. Allergy 1985; 55: 568-570.

7. Williamson H.A. Jr., Schultz P. An association between acute bronchitis and asthma. J. Fam. Pract. 1987; 24: 35-38.

8. Smyrnios N.A., Irwin R.S., Curley F.J., French C.L. From a prospective study of chronic cough: diagnostic and therapeutic aspects in older adults. Arch. Intern. Med. 1998; 158: 1222-1228.

9. Palombini B.C., Villanova C.A., Araujo E. et al. A pathogenic triad in chronic cough: asthma, postnasal drip syndrome, and gastroesophageal reflux disease. Chest 1999; 116: 279-284.

10. McGarvey L.P., Heaney L.G., Lawson J.T. et al. Evaluation and outcome of patients with chronic nonproductive cough using a comprehensive diagnostic protocol. Thorax 1998; 53: 738-743.

11. Woodhead M.A., Macfarlane J.T., McCracken J.S., Rose D.H., Finch R.G. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987; 1: 671-674.

12. Metlay J.P., Kapoor W.N., Fine M.J. Does this patient have communityacquired pneumonia? Diagnosing pneumonia by history and physical examination. J. A. M. A. 1997; 278: 1440-1445.

13. Melbye H., Straume B., Aasebo U., Brox J. The diagnosis of adult pneumonia in general practice. The diagnostic value of history, physical examination and some blood tests. Scand J. Prim. Health. Care 1988; 6: 111-117.

14. Melbye H., Straume B., Brox J. Laboratory tests for pneumonia in general practice: the diagnostic values depend on the duration of illness. Scand J. Prim. Health. Care 1992; 10: 234-240.

15. Stockley R.A., O'Brien C., Pye A., Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638-1645.

16. Dev D., Wallace E., Sankaran R. et al. Value of Creactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir. Med. 1998; 92: 664-667.

17. Hedlund J., Hansson L.O. Procalcitonin and Creactive protein levels in communityacquired pneumonia: correlation with etiology and prognosis. Infection 2000; 28: 68-73.

18. Jonsson J.S., Sigurdsson J.A., Kristinsson K.G., Guthnadottir M., Magnusson S. Acute bronchitis in adults. How close do we come to its aetiology in general practice? Scand J. Prim. Health. Care 1997; 15: 156-160.

19. Reed W.W., Byrd G.S., Gates R.H. Jr., Howard R.S., Weaver M.J. Sputum gram's stain in communityacquired pneumococcal pneumonia. A metaanalysis. West J. Med. 1996; 165: 197-204.

20. Pavesi L., Subburaj S., Porter-Shaw K. Application and validation of a computerized cough acquisition system for objective monitoring of acute cough: a meta-analysis. Chest 2001; 120: 1121-1128.

21. Schroeder K., Fahey T. Overthecounter medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst. Rev. 2001; 3: CD001831.

22. Matthys H., Erhardt J., Ruhle K.H. Objectivation of the effect of antitussive agents using tussometry in patients with chronic cough]. Schweiz. Med. Wochenschr 1985; 115: 307-311.

23. Smucny J.J., Flynn C.A., Becker L.A., Glazier R.H. Are beta-2-agonists effective treatment for acute bronchitis or acute cough in patients without underlying pulmonary disease? A systematic review. J. Fam. Pract. 2001; 50: 945-951.

24. Smucny J., Fahey T., Becker L., Glazier R., McIsaac W. Antibiotics for acute bronchitis. Cochrane Database Syst. Rev. 2000; 4: CD000245.

25. Evans A.T., Husain S., Durairaj L., Sadowski L.S., Charles-Damte M., Wang Y. Azithromycin for acute bronchitis: a randomised, doubleblind, controlled trial. Lancet 2002; 359: 1648-1654.

26. Verheij T.J., Hermans J., Mulder J.D. Effects of doxycycline in patients with acute cough and purulent sputum: a double blind placebo controlled trial. Br. J. Gen. Pract. 1994; 44: 400-404.

27. Saint S., Bent S., Vittinghoff E., Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. J. A. M. A. 1995; 273: 957-960.

28. Allegra L., Blasi F., de Bernardi B., Cosentini R., Tarsia P. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a reevaluation of previously published data of a placebocontrolled randomized study. Pulm. Pharmacol. Ther. 2001; 14: 149-155.

29. Bach P.B., Brown C., Gelfand S.E., McCrory D.C. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann. Intern. Med. 2001; 134: 600-620.

30. Jorgensen A.F., Coolidge J., Pedersen P.A., Petersen K.P., Waldorff S., Widding E. Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis. A doubleblind, placebocontrolled multicentre study in general practice. Scand. J. Prim. Health. Care 1992; 10: 7-11.

31. Sachs A.P., Koeter G.H., Groenier K.H., van der W.D., Schiphuis J., Meyboom-de Jong B. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995; 50: 758-763.

32. Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196-204.

33. Jefferson T.O., Demicheli V., Deeks J.J., Rivetti D. Amantadine and rimantadine for preventing and treating influenza A in adults. Cochrane Database Syst. Rev. 2002; 3: CD001169.

34. Guay D.R. Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective. Drugs Aging. 1994; 5: 8-19.

35. McNicholl I.R., McNicholl J.J. Neuraminidase inhibitors: zanamivir and oseltamivir. Ann. Pharmacother 2001; 35: 57-70.

36. Monto A.S., Webster A., Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J. Antimicrob. Chemother 1999; 44: suppl. B 23-29.

37. Fine M.J., Auble T.E., Yealy D.M. et al. A prediction rule to identify lowrisk patients with communityacquired pneumonia. N. Engl. J. Med. 1997; 336: 243-250.

38. Neill A.M., Martin I.R., Weir R. et al. Communityacquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996; 51: 1010-1016.

39. Lim W.S., Lewis S., Macfarlane J.T. Severity prediction rules in communityacquired pneumonia: a validation study. Thorax 2000; 55: 219-223.

40. Ewig S., Kleinfeld T., Bauer T., Seifert K., Schafer H., Goke N. Comparative validation of prognostic rules for community acquired pneumonia in an elderly population. Eur. Respir.J. 1999; 14: 370-375.

41. Roson B., Carratala J., Dorca J., Casanova A., Manresa F., Gudiol F. Etiology, reasons for hospitalization, risk classes, and outcomes of communityacquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin. Infect. Dis. 2001; 33: 158-165.

42. Marrie T.J., Lau C.Y., Wheeler S.L., Wong C.J., Vandervoort M.K., Feagan B.G. A controlled trial of a critical pathway for treatment of communityacquired pneumonia. CAPITAL Study Investigators. CommunityAcquired Pneumonia Intervention Trial Assessing Levofloxacin. J. A. M. A. 2000; 283: 749-755.

43. Lim W.S., Macfarlane J.T., Boswell T.C. et al. Study of communityacquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56: 296-301.

44. Communityacquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. The British Thoracic Society and the Public Health Laboratory Service. Q. J. Med. 1987; 62: 195-220.

45. Farr B.M., Sloman A.J., Fisch M.J. Predicting death in patients hospitalized for communityacquired pneumonia. Ann. Intern. Med. 1991; 115: 428-436.

46. Karalus N.C, Cursons R.T., Leng R.A. et al. Community acquired pneumonia: aetiology and prognostic index evaluation. Thorax 1991; 46: 413-418.

47. Marras T.K., Gutierrez C., Chan C.K. Applying a prediction rule to identify lowrisk patients with communityacquired pneumonia. Chest. 2000; 118: 1339-1343.

48. Ewig S., Ruiz M., Mensa J. et al. Severe community acquired pneumonia. Assessment of severity criteria. Am. J. Respir. Crit. Care Med. 1998; 158: 1102-1108.

49. Minogue M.F., Coley C.M., Fine M.J., Marrie T.J., KapoorW.N., Singer D.E. Patients hospitalized after initial outpatient treatment for communityacquired pneumonia. Ann. Emerg. Med. 1998; 31: 376-380.

50. Porath A., Schlaeffer F., Lieberman D. Appropriateness of hospitalization of patients with communityacquired pneumonia. Ann. Emerg. Med. 1996; 27: 176-183.

51. Niederman M.S., Mandell L.A., Anzueto A. et al. Guidelines for the management of adults with communityacquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 2001; 163: 1730-1754.

52. Angus D.C., Marrie T.J., Obrosky D.S. et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am. J. Respir. Crit. Care Med. 2002; 166: 717-723.

53. Atlas S.J., Benzer T.I., Borowsky L.H. et al. Safely increasing the proportion of patients with communityacquired pneumonia treated as outpatients: an interventional trial. Arch. Intern. Med. 1998; 158: 1350-1356.

54. Dean N.C., Silver M.P., Bateman K.A., James B., Had- lock C.J., Hale D. Decreased mortality after implementa tion of a treatment guideline for communityacquired pneumonia. Am. J. Med. 2001; 110: 451-457.

55. Levin K.P., Hanusa B.H., Rotondi A. et al. Arterial bloodgas and pulse oximetry in initial management of patients with communityacquired pneumonia. J. Gen Intern. Med. 2001; 16: 590-598.

56. Smith R.P., Lipworth B.J., Cree I.A., Spiers E.M., Winter J.H. Creactive protein. A clinical marker in community acquired pneumonia. Chest. 1995; 108: 1288-1291.

57. Hedlund J., Hansson L.O. Procalcitonin and Creactive protein levels in communityacquired pneumonia: correla tion with etiology and prognosis. Infection 2000; 28: 68-73.

58. Theerthakarai R., El Halees W., Ismail M., Solis R.A., Khan M.A. Nonvalue of the initial microbiological studies in the management of nonsevere community-acquired pneumonia. Chest 2001; 119: 181-184.

59. Sanyal S., Smith P.R., Saha A.C., Gupta S., Berkowitz L., Homel P. Initial microbiologic studies did not affect out come in adults hospitalized with community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 1999; 160: 346-348.

60. Lieberman D., Schlaeffer F., Boldur I. et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51: 179-184.

61. Ruiz M., Ewig S., Marcos M.A. et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am. J. Respir. Crit. Care Med. 1999; 160: 397-405.

62. Waterer G.W., Somes G.W., Wunderink R.G. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch. Intern. Med. 2001; 161: 1837-1842.

63. Marrie T.J., Haldane E.V., Faulkner R.S., Durant H., Kwan C. Communityacquired pneumonia requiring hospitalization. Is it different in the elderly? J. Am. Geriatr. Soc. 1985; 33: 671-680.

64. Marston B.J., Plouffe J.F., File T.M. Jr. et al. Incidence of communityacquired pneumonia requiring hospitalization. Results of a populationbased active surveillance Study in Ohio. The CommunityBased Pneumonia Incidence Study Group. Arch. Intern. Med. 1997; 157: 1709-1718.

65. Macfarlane J.T., Colville A., Guion A., Macfarlane R.M., Rose D.H. Prospective study of aetiology and outcome of adult lowerrespiratorytract infections in the community. Lancet 1993; 341: 511-514.

66. Bishara J., Leibovici L., Ashkenazi S., Samra Z., Pitlik S. Sevenyear study of bacteraemic pneumonia in a single institution. Eur. J. Clin. Microbiol. Infect. Dis. 2000; 19: 926-931.

67. Kalin M., Lindberg A.A. Diagnosis of pneumococcal pneumonia: a comparison between microscopic examination of expectorate, antigen detection and cultural procedures. Scand. J. Infect. Dis. 1983; 15: 247-255.

68. Marrie T.J., Durant H., Yates L. Communityacquired pneumonia requiring hospitalization: 5year prospective study. Rev. Infect. Dis.1989; 11: 586-599.

69. Gleckman R., DeVita J., Hibert D., Pelletier C., Martin R. Sputum gram stain assessment in communityacquired bacteremic pneumonia. J. Clin. Microbiol 1988; 26: 846-849.

70. Skerrett S.J. Diagnostic testing for communityacquired pneumonia. Clin. Chest. Med. 1999; 20: 531-548.

71. Ruiz-Gonzalez A., Nogues A., Falguera M., Porcel J.M., Huelin E., Rubio-Caballero M. Rapid detection of pneumococcal antigen in lung aspirates: comparison with culture and PCR technique. Respir. Med. 1997; 91: 201-206.

72. Ruiz-Gonzalez A., Falguera M., Nogues A., Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am. J. Med. 1999; 106: 385-390.

73. Garcia A., Roson B., Perez J.L. et al. Usefulness of PCR and antigen latex agglutination test with samples obtained by transthoracic needle aspiration for diagnosis of pneumo coccal pneumonia. J. Clin. Microbiol. 1999; 37: 709-714.

74. Scott J.A., Hall A.J. The value and complications of percutaneous transthoracic lung aspiration for the etiologic diagnosis of communityacquired pneumonia. Chest 1999; 116: 1716-1732.

75. Ishida T., Hashimoto T., Arita M. et al. Efficacy of trans thoracic needle aspiration in communityacquired pneumonia. Intern. Med. 2001; 40: 873-877.

76. Clark B.D., Vezza P.R., Copeland C., Wilder A.M., Abati A. Diagnostic sensitivity of bronchoalveolar lavage versus lung fine needle aspirate. Mod. Pathol. 2002; 15: 1259-1265.

77. Wimberley N., Faling L.J., Bartlett J.G. A fiberoptic bronchoscopy technique to obtain uncontaminated lower airway secretions for bacterial culture. Am. Rev. Respir. Dis. 1979; 119: 337-343.

78. Wearden P.D., Chendrasekhar A., Timberlake G.A. Comparison of nonbronchoscopic techniques with bronchoscopic brushing in the diagnosis of ventilatorassociated pneumonia. J. Trauma 1996; 41: 703-707.

79. Bello S., Tajada A., Chacon E. et al. "Blind" protected specimen brushing versus bronchoscopic techniques in the aetiolological diagnosis of ventilatorassociated pneumonia. Eur. Respir J. 1996; 9: 1494-1499.

80. Thorpe J.E., Baughman R.P., Frame P.T., Wesseler T.A., Staneck J.L. Bronchoalveolar lavage for diagnosing acute bacterial pneumonia. J. Infect. Dis. 1987; 155: 855-861.

81. Meduri G.U., Beals D.H., Maijub A.G., Baselski V. Protected bronchoalveolar lavage. A new bronchoscopic technique to retrieve uncontaminated distal airway secretions. Am. Rev. Respir. Dis. 1991; 143: 855-864.

82. Pereira-Gomes J.C., Pedreira J.W. Jr., Araujo E.M. et al. Impact of BAL in the management of pneumonia with treatment failure: positivity of BAL culture under antibiotic therapy. Chest 2000; 118: 1739-1746.

83. Rasmussen T.R., Korsgaard J., Moller J.K., Sommer T., Kilian M. Quantitative culture of bronchoalveolar lavage fluid in communityacquired lower respiratory tract infections. Respir. Med. 2001; 95: 885-890.

84. Cantral D.E., Tape T.G., Reed E.C., Spurzem J.R., Rennard S.I., Thompson A.B. Quantitative culture of bronchoalveolar lavage fluid for the diagnosis of bacterial pneumonia. Am. J. Med. 1993; 95: 601-607.

85. Chastre J., Viau F., Brun P. et al. Prospective evaluation of the protected specimen brush for the diagnosis of pulmonary infections in ventilated patients. Am. Rev. Respir. Dis. 1984; 130: 924-929.

86. Torres A., El Ebiary M. Bronchoscopic BAL in the diagnosis of ventilatorassociated pneumonia. Chest 2000; 117: suppl. 2 198S-202S.

87. Rodriguez R.M., Fancher M.L., Phelps M. et al. An emergency departmentbased randomized trial of nonbronchoscopic bronchoalveolar lavage for early pathogen identification in severe communityacquired pneumonia. Ann. Emerg. Med. 2001; 38: 357-363.

88. Nagendra S., Bourbeau P., Brecher S., Dunne M., LaRocco M., Doern G. Sampling variability in the microbiological evaluation of expectorated sputa and endotracheal aspirates. J. Clin. Microbiol. 2001; 39: 2344-2347.

89. Cooper G.M., Jones J.J., Arbique J.C., Flowerdew G.J., Forward K.R. Intra and inter technologist variability in the quality assessment of respiratory tract specimens. Diagn. Microbiol. Infect. Dis 2000; 37: 231-235.

90. Reed W.W., Byrd G.S., Gates R.H. Jr., Howard R.S., Weaver M.J. Sputum gram's stain in communityacquired pneumococcal pneumonia. A metaanalysis. West J. Med. 1996; 165: 197-204.

91. Drew W.L. Value of sputum culture in diagnosis of pneumococcal pneumonia. J. Clin. Microbiol. 1977; 6: 62-65.

92. Roson B., Carratala J., Verdaguer R., Dorca J., Manresa F., Gudiol F. Prospective study of the usefulness of sputum Gram stain in the initial approach to communityacquired pneumonia requiring hospitalization. Clin. Infect. Dis. 2000; 31: 869-874.

93. Ewig S., Schlochtermeier M., Goke N., Niederman M.S. Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions. Chest. 2002; 121: 1486-1492.

94. Geckler R.W., Gremillion D.H., McAllister C.K., Ellenbogen C. Microscopic and bacteriological comparison of paired sputa and transtracheal aspirates. J. Clin. Microbiol. 1977; 6: 396-399.

95. Parry C.M., White R.R., Ridgeway E.R., Corkill J.E., Smith G.W. The reproducibility of sputum gram film interpretation. J. Infect. 2000; 41: 55-60.

96. Geckler R.W., McAllister C.K., Gremillion D.H., Ellenbogen C. Clinical value of paired sputum and transtracheal aspirates in the initial management of pneumonia. Chest 1985; 87: 631-635.

97. Bartlett J.G., Finegold S.M. Bacteriology of expectorated sputum with quantitative culture and wash technique com pared to transtracheal aspirates. Am. Rev. Respir. Dis. 1978; 117: 1019-1027.

98. Lentino J.R., Lucks D.A. Nonvalue of sputum culture in the management of lower respiratory tract infections. J. Clin. Microbiol. 1987; 25:758-762.

99. Barrett-Connor E. The nonvalue of sputum culture in the diagnosis of pneumococcal pneumonia. Am. Rev. Respir. Dis. 1971; 103: 845-848.

100. Murdoch D.R., Laing R.T., Mills G.D. et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with communityacquired pneumonia. J. Clin. Microbio.l 2001; 39: 3495-3498.

101. Dominguez J., Gali N., Blanco S. et al. Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest 2001; 119: 243-249.

102. Burel E., Dufour P., Gauduchon V., Jarraud S., Etienne J. Evaluation of a rapid immunochromatographic assay for detection of Streptococcus pneumoniae antigen in urine samples. Eur. J. Clin. Microbiol. Infect. Dis. 2001; 20: 840-841.

103. Benson R.F., Tang P.W., Fields B.S. Evaluation of the Binax and Biotest urinary antigen kits for detection of Legionnaires' disease due to multiple serogroups and species of Legionella. J. Clin. Microbiol. 2000; 38: 2763-2765.

104. Dominguez J.A., Gali N., Pedroso P. et al. Comparison of the Binax Legionella urinary antigen enzyme immunoassay (EIA) with the Biotest Legionella Urin antigen EIA for detection of Legionella antigen in both concentrated and nonconcentrated urine samples. J. Clin. Microbiol. 1998; 36: 2718-2722.

105. Dominguez J., Gali N., Matas L. et al. Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples. Eur. J. Clin. Microbiol. Infect. Dis. 1999; 18: 896-898.

106. Bernander S., Gastrin B., Lofgren S., Olinder-Nielsen A.M. Legionella urinary antigen in early disease. Scand. J. Infect. Dis. 1994; 26: 777-778.

107. Yzerman E.P., den Boer J.W., Lettinga K.D., Schellekens J., Dankert J., Peeters M. Sensitivity of three urinary antigen-tests associated with clinical severity in a large outbreak of Legionnaires' disease in The Netherlands. J. Clin. Microbiol. 2002; 40: 3232-3236.

108. Irmen K.E., Kelleher J.J. Use of monoclonal antibodies for rapid diagnosis of respiratory viruses in a community hospital. Clin. Diagn. Lab. Immunol. 2000; 7: 396-403.

109. Reina J., Padilla E., Alonso F., Ruiz De Gopegui E., Munar M., Mari M. Evaluation of a new dot blot enzyme immunoassay (directigen flu A+B) for simultaneous and differential detection of influenza a and B virus antigens from respira tory samples. J. Clin. Microbiol. 2002; 40: 3515-3517.

110. Vikerfors T., Brodin G., Grandien M., Hirschberg L., Krook A., Pettersson C.A. Detection of specific IgM antibodies for the diagnosis of Mycoplasma pneumoniae infections: a clinical evaluation. Scand. J. Infect. Dis. 1988; 20: 601-610.

111. Dorigo-Zetsma J.W., Zaat S.A., Wertheim-van Dillen P.M. et al. Comparison of PCR, culture, and serological tests for diagnosis of Mycoplasma pneumoniae respiratory tract infection in children. J. Clin. Microbiol. 1999; 37: 14-17.

112. Thacker W.L., Talkington D.F. Comparison of two rapid commercial tests with complement fixation for serologic diagnosis of Mycoplasma pneumoniae infections. J. Clin. Microbiol. 1995; 33: 1212-1214.

113. Thacker W.L., Talkington D.F. Analysis of complement fixation and commercial enzyme immunoassays for detection of antibodies to Mycoplasma pneumoniae in human serum. Clin. Diagn. Lab. Immunol. 2000; 7: 778-780.

114. Ramirez J.A., Ahkee S., Tolentino A., Miller R.D., Summersgill J.T. Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae, or Chlamydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab specimen. Diagn. Microbiol. Infect. Dis. 1996; 24: 7-14.

115. Grayston J.T., Aldous M.B., Easton A. et al. Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis. J. Infect. Dis. 1993; 168: 1231-1235.

116. Plouffe J.F., File T.M. Jr., Breiman R.F. et al. Reevaluation of the definition of Legionnaires' disease: use of the urinary antigen assay. Community Based Pneumonia Incidence Study Group. Clin. Infect. Dis. 1995; 20: 1286-1291.

117. Petitjean J., Vabret A., Gouarin S., Freymuth F. Evaluation of four commercial immunoglobulin G (IgG) and IgM specific enzyme immunoassays for diagnosis of Mycoplasma pneumoniae infections. J. Clin. Microbiol. 2002; 40: 165-171.

118. Herrmann B., Larsson C., Zweygberg B.W. Simultaneous detection and typing of influenza viruses A and B by a nested reverse transcriptionPCR: comparison to virus isolation and antigen detection by immunofluorescence and optical immunoassay (FLU OIA). J. Clin. Microbiol. 2001; 39: 134-138.

119. Helms C.M., Viner J.P., Sturm R.H., Renner E.D., Johnson W. Comparative features of pneumococcal, mycoplasmal, and Legionnaires' disease pneumonias. Ann. Intern. Med. 1979; 90: 543-547.

120. Woodhead M.A., Macfarlane J.T. Comparative clinical and laboratory features of legionella with pneumococcal and mycoplasma pneumonias. Br. J. Dis.Chest. 1987; 81: 133-139.

121. Kauppinen M.T., Saikku P., Kujala P., Herva E., Syrjala H. Clinical picture of communityacquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax 1996; 51: 185-189.

122. Farr B.M., Kaiser D.L., Harrison B.D., Connolly C.K. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. British Thoracic Society Pneumonia Research Subcommittee. Thorax 1989; 44: 1031-1035.

123. Tang C.M., Macfarlane J.T. Early management of younger adults dying of communityacquired pneumonia. Respir. Med. 1993; 87: 289-294.

124. Meehan T.P., Fine M.J., Krumholz H.M. et al. Quality of care, process, and outcomes in elderly patients with pneumonia. J. A. M. A. 1997; 278: 2080-2084.

125. Simpson J.C., Macfarlane J.T., Watson J., Woodhead M.A. A national confidential enquiry into communityacquired pneumonia deaths in young adults in England and Wales. British Thoracic Society Research Committee and Public Health Laboratory Service. Thorax 2000; 55: 1040-1045.

126. Leroy O., Santre C, Beuscart C. et al. A fiveyear study of severe communityacquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995; 21: 24-31.

127. Fang G.D., Fine M., Orloff J. et al. New and emerging etiologies for communityacquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) 1990; 69: 307-316.

128. Bohte R., van Furth R., van den Broek P.J. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995; 50: 543-547.

129. Gomez J., Banos V., Ruiz G.J. et al. Prospective study of epidemiology and prognostic factors in community-acquired pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 1996; 15: 556-560.

130. Steinhoff D., Lode H., Ruckdeschel G. et al. Chlamydia pneumoniae as a cause of communityacquired pneumonia in hospitalized patients in Berlin. Clin. Infect. Dis. 1996; 22: 958-964.

131. Sopena N., Sabria M., Pedro-Botet M.L. et al. Prospective study of communityacquired pneumonia of bacterial etiology in adults. Eur. J. Clin. Microbiol. Infect. Dis. 1999; 18: 852-858.

132. Socan M., Marinic-Fiser N., Kraigher A., Kotnik A., Logar M. Microbial aetiology of communityacquired pneumonia in hospitalised patients. Eur. J. Clin. Microbiol. Infect. Dis. 1999; 18: 777-782.

133. Falguera M., Sacristan O., Nogues A. et al. Nonsevere communityacquired pneumonia: correlation between cause and severity or comorbidity. Arch. Intern. Med. 2001; 161: 1866-1872.

134. Arancibia F., Bauer T.T., Ewig S. et al. Community-acquired pneumonia due to gramnegative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch. Intern. Med. 2002; 162: 1849-1858.

135. Torres A., Serra-Batlles J., Ferrer A. et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am. Rev. Respir. Dis. 1991; 144: 312-318.

136. Marik P.E. The clinical features of severe community acquired pneumonia presenting as septic shock. Norasept II Study Investigators. J. Crit. Care. 2000; 15: 85-90.

137. Arancibia F., Ewig S., Martinez J.A. et al. Antimicrobial treatment failures in patients with communityacquired pneumonia: causes and prognostic implications. Am. J. Respir. Crit. Care. Med. 2000; 162: 154-160.

138. Hatchette T.F., Gupta R., Marrie T.J. Pseudomonas aeruginosa communityacquired pneumonia in previously healthy adults: case report and review of the literature. Clin. Infect. Dis. 2000; 31: 1349-1356.

139. Riquelme R., Torres A., El Ebiary M. et al. Community acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors. Am. J. Respir. Crit. Care Med. 1996; 154: 1450-1455.

140. Venkatesan P., Gladman J., Macfarlane J.T. et al. A hospital study of communityacquired pneumonia in the elderly. Thorax 1990; 45: 254-258.

141. Metlay J.P., Hofmann J., Cetron M.S. et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30: 520-528.

142. Lynch IIIJ.P., Martinez F.J. Clinical relevance of macrolideresistant Streptococcus pneumoniae for community-acquired pneumonia. Clin. Infect. Dis. 2002; 34: suppl. 1 S27-S46.

143. Lonks J.R., Garau J., Gomez L. et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycinresistant Streptococcus pneumoniae. Clin. Infect. Dis. 2002; 35: 556-564.

144. Empey P.E., Jennings H.R., Thornton A.C., Rapp R.P., Evans M.E. Levofloxacin failure in a patient with pneumococcal pneumonia. Ann. Pharmacother 2001; 35: 687-690.

145. Ho P.L., Tse W.S., Tsang K.W. et al. Risk factors for acquisition of levofloxacinresistant Streptococcus pneumoniae: a casecontrol study. Clin. Infect. Dis. 2001; 32: 701-707.

146. Davidson R., Cavalcanti R., Brunton J.L. et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 2002; 346: 747-750.

147. Pallares R., Linares J., Vadillo M. et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N. Engl. J. Med. 1995; 333: 474-480.

148. Moroney J.F., Fiore A.E., Harrison L.H. et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin. Infect. Dis. 2001; 33: 797-805.

149. Felmingham D., Gruneberg R.N. The Alexander Project 1996-1997: latest susceptibility data from this internation al study of bacterial pathogens from communityacquired lower respiratory tract infections. J. Antimicrob Chemother 2000; 45: 191-203.

150. Fluit A.C., Schmitz F.J., Jones M.E., Acar J., Gupta R., Verhoef J. Antimicrobial resistance among community-acquired pneumonia isolates in Europe: first results from the SENTRY antimicrobial surveillance program 1997. SENTRY Participants Group. Int. J. Infect. Dis. 1999; 3: 153-156.

151. Pedersen G., Schonheyder H.C., Steffensen F.H., Sorensen H.T. Risk of resistance related to antibiotic use before admission in patients with communityacquired bacteraemia. J. Antimicrob. Chemother 1999; 43: 119-126.

152. Benenson R., Magalski A., Cavanaugh S., Williams E. Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality. Acad. Emerg. Med. 1999; 6: 1243-1248.

153. Ewig S., Seifert K., Kleinfeld T., Goke N., Schafer H. Management of patients with communityacquired pneumonia in a primary care hospital: a critical evaluation. Respir. Med. 2000; 94: 556-563.

154. Meehan T.P., Weingarten S.R., Holmboe E.S. et al. A statewide initiative to improve the care of hospitalized pneumonia patients: The Connecticut Pneumonia Pathway Project. Am. J. Med. 2001; 111: 203-210.

155. Hirani N.A., Macfarlane J.T. Impact of management guidelines on the outcome of severe communityacquired pneumonia. Thorax 1997; 52: 17-21.

156. Gleason P.P., Meehan T.P., Fine J.M., Galusha D.H., Fine M.J. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch. Intern. Med. 1999; 159: 2562-2572.

157. Burgess D.S., Lewis J.S. Effect of macrolides as part of ini tial empiric therapy on medical outcomes for hospitalized patients with communityacquired pneumonia. Clin. Ther. 2000; 22: 872-878.

158. Mundy L.M., Oldach D., Auwaerter P.G. et al. Implications for macrolide treatment in communityacquired pneumo nia. Hopkins CAP Team. Chest 1998; 113: 1201-1206.

159. Cabellos C., Ariza J., Barreiro B. et al. Current usefulness of procaine penicillin in the treatment of pneumococcal pneumonia. Eur. J. Clin. Microbiol. Infect. Dis. 1998; 17: 265-268.

160. Pachon J., Prados M.D., Capote F., Cuello J.A., Garnacho J., Verano A. Severe communityacquired pneumonia. Etiology, prognosis, and treatment. Am. Rev. Respir. Dis. 1990; 142: 369-373.

161. Schentag J.J. Antimicrobial action and pharmacokinetics / pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. J. Chemother 1999; 11: 426-439.

162. Ramirez J.A., Srinath L., Ahkee S., Huang A., Raff M.J. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community acquired pneumonia. Arch. Intern. Med. 1995; 155: 1273-1276.

163. Ramirez J.A., Vargas S., Ritter G.W. et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with communityacquired pneumonia. Arch. Intern. Med. 1999; 159: 2449-2454.

164. Siegel R.E, Halpern N.A., Almenoff P.L., Lee A., Cashin R., Greene J.G. A prospective randomized study of inpatient iv. antibiotics for communityacquired pneumonia. The optimal duration of therapy. Chest 1996; 110: 965-971.

165. Dunn A.S., Peterson K.L., Schechter C.B., Rabito P., Got lin A.D., Smith L.G. The utility of an inhospital observation period after discontinuing intravenous antibiotics. Am. J. Med. 1999; 106: 6-10.

166. Ramirez J.A., Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch. Intern. Med. 2001; 161: 848-850.

167. Sanders W.E. Jr., Morris J.F., Alessi P. et al. Oral ofloxacin for the treatment of acute bacterial pneumonia: use of a nontraditional protocol to compare experimental therapy with "usual care" in a multicenter clinical trial. Am. J. Med. 1991; 91: 261-266.

168. Castro-Guardiola A., Viejo-Rodriguez A.L., Soler-Simon S. et al. Efficacy and safety of oral and earlyswitch therapy for communityacquired pneumonia: a randomized con trolled trial. Am. J. Med. 2001; 111: 367-374.

169. Rhew D.C., Riedinger M.S., Sandhu M., Bowers C., Greengold N., Weingarten S.R. A prospective, multicenter study of a pneumonia practice guideline. Chest 1998; 114: 115-119.

170. Rhew D.C., Tu G.S., Ofman J., Henning J.M., Richards M.S., Weingarten S.R. Early switch and early discharge strategies in patients with communityacquired pneumonia: a meta analysis. Arch. Intern. Med. 2001; 161: 722-727.

171. File T.M.Jr., Segreti J., Dunbar L. et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and / or oral levofloxacin versus ceftriaxone and / or cefuroxime axetil in treatment of adults with community acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965-1972.

172. Finch R., Schurmann D., Collins O. et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral coamoxiclav with or without clarithromycin in patients with com munityacquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46: 1746-1754.

173. Samama M.M., Cohen A.T., Darmon J.Y. et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N. Engl. J. Med. 1999; 341: 793-800.

174. Confalonieri M., Potena A., Carbone G., Porta R.D., Tolley E.A., Umberto M.G. Acute respiratory failure in patients with severe communityacquired pneumonia. A prospective randomized evaluation of noninvasive ventilation. Am. J. Respir. Crit. Care Med. 1999; 160: 1585-1591.

175. Jolliet P., Abajo B., Pasquina P., Chevrolet J.C. Noninvasive pressure support ventilation in severe community acquired pneumonia. Intensive Care Med. 2001; 27: 812-821.

176. International Consensus Conferences in Intensive Care Medicine: noninvasive positive pressure ventilation in acute respiratory failure. Am. J. Respir. Crit. Care Med. 2001; 163: 283-291.

177. Nelson S., Heyder A.M., Stone J. et al. A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J. Infect. Dis. 2000; 182: 970-973.

178. Metlay J.P., Atlas S.J., Borowsky L.H., Singer D.E. Time course of symptom resolution in patients with community acquired pneumonia. Respir. Med. 1998; 92: 1137-1142.

179. Macfarlane J.T., Miller A.C., Roderick Smith W.H., Mor ris A.H., Rose D.H. Comparative radiographic features of community-acquired Legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia, and psittacosis. Thorax 1984; 39: 28-33.

180. Mittl R.L. Jr., Schwab R.J., Duchin J.S., Goin J.E., Albeida S.M., Miller W.T. Radiographic resolution of community-acquired pneumonia. Am. J. Respir. Crit. Care Med. 1994; 149: 630-635.

181. Halm E.A., Fine M.J., Marrie T.J. et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. J. A. M. A. 1998; 279: 1452-1457.

182. Halm E.A., Fine M.J., Kapoor W.N., Singer D.E., Marrie T.J., Siu A.L. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch. Intern. Med. 2002; 162: 1278-1284.

183. Fine M.J., Pratt H.M., Obrosky D.S. et al. Relation between length of hospital stay and costs of care for patients with community-acquired pneumonia. Am. J. Med. 2000; 109: 378-385.

184. Menendez R., Ferrando D., Valles J.M., Martinez E., Perpina M. Initial risk class and length of hospital stay in community-acquired pneumonia. Eur. Respir. J. 2001; 18: 151-156.

185. McCormick D., Fine M.J., Coley C.M. et al. Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes? Am. J. Med. 1999; 107: 5-12.

186. Metersky M.L., Tate J.P., Fine M.J., Petrillo M.K., Meehan T.P. Temporal trends in outcomes of older patients with pneumonia. Arch. Intern. Med. 2000; 160: 3385-3391.

187. Halm E.A., Switzer G.E., Mittman B.S., Walsh M.B., Chang C.C., Fine M.J. What factors influence physicians' decisions to switch from intravenous to oral antibiotics for communityacquired pneumonia? J. Gen. Intern. Med. 2001; 16: 599-605.

188. Feinsilver S.H., Fein A.M., Niederman M.S., Schultz D.E., Faegenburg D.H. Utility of fiberoptic bronchoscopy in nonresolving pneumonia. Chest. 1990; 98: 1322-1326.

189. Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932-946.

190. Garcia-Aymerich J., Monso E., Marrades R.M. et al. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. Am. J. Respir. Crit. Care Med.2001; 164: 1002-1007.

191. Nouira S., Marghli S., Belghith M., Besbes L., Elatrous S., Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebocontrolled trial. Lancet 2001; 358: 2020-2025.

192. McCrory D.C., Brown C., Gelfand S.E., Bach P.B. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest 2001; 119: 1190-1209.

193. Monso E., Ruiz J., Rosell A. et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am. J. Respir. Crit. Care Med. 1995; 152: 1316-1320.

194. Sethi S., Evans N., Grant B.J., Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 2002; 347: 465-471.

195. Monso E., Rosell A., Bonet G. et al. Risk factors for lower airway bacterial colonization in chronic bronchitis. Eur. Respir. J. 1999; 13: 338-342.

196. Soler N., Torres A., Ewig S. et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am. J. Respir. Crit. Care Med. 1998; 157: 1498-1505.

197. Fagon J.Y., Chastre J., Trouillet J.L. et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am. Rev. Respir. Dis. 1990; 142: 1004-1008.

198. Miravitlles M., Espinosa C., Fernandez-Laso E., Martos J.A., Maldonado J.A., Gallego M. Relationship between bacteri al flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116: 40-46.

199. Eller J., Ede A., Schaberg T., Niederman M.S., Mauch H., Lode H. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542-1548.

200. Mogulkoc N., Karakurt S., Isalska B. et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am. J. Respir. Crit. Care Med. 1999; 160: 349-353.

201. Lieberman D., Ben Yaakov M., Lazarovich Z., Ohana B., Boldur I. Chlamydia pneumoniae infection in acute exacerbations of chronic obstructive pulmonary disease: analysis of 250 hospitalizations. Eur. J. Clin. Microbio. Infect. Dis. 2001; 20: 698-704.

202. Seemungal T., Harper-Owen R., Bhowmik A. et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 1618-1623.

203. Ewig S., Soler N., Gonzalez J., Celis R., El Ebiary M., Torres A. Evaluation of antimicrobial treatment in mechanically ven tilated patients with severe chronic obstructive pulmonary disease exacerbations. Crit. Care Med. 2000; 28: 692-697.

204. Anzueto A., Niederman M.S., Haverstock D.C., Tillotson G.S. Efficacy of ciprofloxacin and clarithromycin in acute bac terial exacerbations of complicated chronic bronchitis: interim analysis. Bronchitis Study Group. Clin. Ther 1997; 19: 989-1001.

205. Adams S.G., Melo J., Luther M., Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000; 117: 1345-1352.

206. Pang J.A., Cheng A., Chan H.S., Poon D., French G. The bacteriology of bronchiectasis in Hong Kong investigated by protected catheter brush and bronchoalveolar lavage. Am. Rev. Respir. Dis. 1989; 139: 14-17.

207. Cabello H., Torres A., Celis R. et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur. Respir. J. 1997; 10: 1137-1144.

208. Angrill J., Agusti C., de Celis R. et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57: 15-19.

209. Pela R., Marchesani F., Agostinelli C. et al. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation. Monaldi Arch. Chest. Dis. 1998; 53: 262-267.

210. Groeneveld K., van Alphen L., Eijk P.P., Visschers G., Jansen H.M., Zanen H.C. Endogenous and exogenous reinfections by Haemophilus influenzae in patients with chronic obstructive pulmonary disease: the effect of antibiotic treatment on persistence. J. Infect. Dis. 1990; 161: 512-517.

211. Hill A.T, Bayley D., Stockley R.A. The interrelationship of sputum inflammatory markers in patients with chronic bron chitis. Am. J. Respir. Crit. Care Med. 1999; 160: 893-898.

212. Ball P., Make B. Acute exacerbations of chronic bronchitis: an international comparison. Chest 1998; 113: suppl. 3 199S-204S.

213. Biebuyck X.A. Comparison of azithromycin and coamoxiclav in the treatment of acute tracheobronchitis and acute infectious exacerbations of chronic bronchitis in adults. Azithromycin Study Group. J. Int. Med. Res. 1996; 24: 407-418.

214. Aubier M., Aldons P.M., Leak A. et al. Telithromycin is as effective as amoxicillin / clavulanate in acute exacerbations of chronic bronchitis. Respir. Med. 2002; 96: 862-871.

215. Blondeau J.M., Tillotson G.S. Antimicrobial susceptibility patterns of respiratory pathogens-a global perspective. Semin. Respir. Infect. 2000; 15: 195-207.

216. Langan C.E., Cranfield R., Breisch S., Pettit R. Randomized, doubleblind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis. J. Antimicrob Chemother 1997; 40: suppl. A 63-72.

217. Wilson R., Kubin R., Ballin I. et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J. Antimicrob Chemother 1999; 44: 501-513.

218. Lorenz J., Thate-Waschke I.M., Mast O. et al. Treatment outcomes in acute exacerbations of chronic bronchitis: comparison of macrolides and moxifloxacin from the patient perspective. J. Int. Med. Res 2001; 29: 74-86.

219. Shah P.M., Maesen F.P., Dolmann A., Vetter N., Fiss E., Wesch R. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, doubleblind study. J. Antimicrob. Chemother. 1999; 43: 529-539.

220. Grossman R.F. Costeffective therapy for acute exacerbations of chronic bronchitis. Semin. Respir. Infect. 2000; 15: 71-81.

221. Miravitlles M. Treatment failure of acute exacerbations of chronic obstructive airways disease risk factors and clinical relevance. Med. Clin. (Barc) 2002; 119: 304-314.

222. Dewan N.A., Rafique S., Kanwar B. et al. Acute exacerbation of COPD: factors associated with poor treatment out ome. Chest 2000; 117: 662-671.

223. Chodosh S., DeAbate C.A., Haverstock D., Aneiro L., Church D. Shortcourse moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir. Med. 2000; 94: 18-27.

224. DeAbate C.A., Mathew C.P., Warner J.H., Heyd A., Church D. The safety and efficacy of short course (5 day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir. Med. 2000; 94: 1029-1037.

225. Pasteur M.C., Helliwell S.M., Houghton S.J. et al. An investigation into causative factors in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 2000; 162: 1277-1284.

226. Ho P.L., Chan K.N., Ip M.S. et al. The effect of Pseudo monas aeruginosa infection on clinical parameters in steadystate bronchiectasis. Chest 1998; 114: 1594-1598.

227. Evans S.A., Turner S.M., Bosch B.J., Hardy C.C., Woodhead M.A. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur. Respir J. 1996; 9: 1601-1604.

228. Miszkiel K.A., Wells A.U., Rubens M.B., Cole P.J, Hansell D.M. Effects of airway infection by Pseudomonas aeruginosa: a computed tomographic study. Thorax 1997; 52: 260-264.

229. Angrill J., Agusti C., de Celis R. et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am. J. Respir. Crit. Care Med. 2001; 164: 1628-1632.

230. Shah P.L., Mawdsley S., Nash K., Cullinan P., Cole P.J., Wilson R. Determinants of chronic infection with Staphylococcus aureus in patients with bronchiectasis. Eur. Respir. J. 1999; 14: 1340-1344.

231. Mitchell J.L., Hill S.L. Immune response to Haemophilus parainfluenzae in patients with chronic obstructive lung disease. Clin. Diagn. Lab. Immunol. 2000; 7: 25-30.

232. Tsang K.W., Chan W.M., Ho P.L., Chan K., Lam W.K., Ip M.S. A comparative study on the efficacy of levofloxacin and ceftazidime in acute exacerbation of bronchiectasis. Eur. Respir. J. 1999; 14: 1206-1209.

233. Foxwell A.R., Cripps A.W., Dear K.B. Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Cochrane Database Syst. Rev. 2003; 3: CD001958.

234. Orcel B., Delclaux B., Baud M., Derenne J.P. Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. Eur. Respir. J. 1994; 7: 446-452.

235. Collet J.P., Shapiro P., Ernst P., Renzi T., Ducruet T., Robinson A. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARIIS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. Am. J. Respir. Crit. Care Med. 1997; 156: 1719-1724.

236. Johnston R.N., McNeill R.S., Smith D.H. et al. Fiveyear winter chemoprophylaxis for chronic bronchitis. Brit. Med. J. 1969; 4: 265-269.

237. Value of chemoprophylaxis and chemotherapy in early chronic bronchitis. A report to the Medical Research Council by their working party on trials of chemotherapy in early chronic bronchitis. BMJ 1966; 5499: 1317-1322.

238. Pridie R.B., Datta N., Massey D.G., Poole G.W., Schneeweiss J., Stradling P. A trial of continuous winter chemotherapy in chronic bronchitis. Lancet 1960; 2: 723-727.

239. Gadomski A.M. Potential interventions for preventing pneumonia among young children: lack of effect of antibiotic treatment for upper respiratory infections. Pediatr. Infect.Dis. J. 1993; 12: 115-120.

240. Arroll B., Kenealy T. Antibiotics for the common cold. Cochrane Database Syst. Rev. 2000; 2: CD000247.

241. Jefferson T.O., Tyrrell D. Antivirals for the common cold. Cochrane Database Syst. Rev. 2001; 3: CD002743.

242. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997; 52: suppl. 5 S1-28.

243. Pauwels R.A., Buist A.S., Calverley P.M., Jenkins C.R., Hurd S.S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am. J. Respir. Crit. Care Med. 2001; 163: 1256-1276.

244. Jones A.P., Rowe B.H. Bronchopulmonary hygiene physical therapy for chronic obstructive pulmonary disease and bronchiectasis. Cochrane Database Syst. Rev. 2000; 2: CD000045.

245. Hayden F.G., Atmar R.L., Schilling M. et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N. Engl. J. Med. 1999; 341: 1336-1343.

246. Hayden F.G., Gubareva L.V., Monto A.S. et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N. Engl. J. Med. 2000; 343: 1282-1289.

247. Monto A.S., Robinson D.P., Herlocher M.L., Hinson J.M. Jr., Elliott M.J., Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999; 282: 31-35.

248. Monto A.S., Pichichero M.E., Blanckenberg S.J. et al. Zanamivir prophylaxis: an effective strategy for the preven tion of influenza types A and B within households. J. Infect. Dis. 2002; 186: 1582-1588.

249. Jefferson T., Demicheli V., Deeks J., Rivetti D. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst. Rev. 2000; 2: CD001265.

250. Poole P.J., Black P.N. Mucolytic agents for chronic bron chitis or chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2000; 2: CD001287.

251. Stey C., Steurer J., Bachmann S., Medici T.C., Tramer M.R. The effect of oral Nacetylcysteine in chronic bronchitis: a quantitative systematic review. Eur. Respir. J. 2000; 16: 253-262.

252. Crockett A.J., Cranston J.M., Latimer K.M., Alpers J.H. Mucolytics for bronchiectasis. Cochrane Database Syst. Rev. 2001; 1: CD001289.

253. Melchart D., Linde K., Fischer P., Kaesmayr J. Echinacea for preventing and treating the common cold. Cochrane Database Syst. Rev. 2000; 2: CD000530.

254. Belongia E.A., Berg R., Liu K. A randomized trial of zinc nasal spray for the treatment of upper respiratory illness in adults. Am. J. Med. 2001; 111: 103-108.

255. Marshall I. Zinc for the common cold. Cochrane Database Syst. Rev. 2000; 2: CD001364.

256. Jackson J.L., Lesho E., Peterson C. Zinc and the common cold: a metaanalysis revisited. J. Nutr. 2000; 130: suppl. 5: 1512S-1515S.

257. Vickers A.J., Smith C. Homoeopathic oscillococcinum for preventing and treating influenza and influenzalike syndromes. Cochrane Database Syst. Rev. 2000; 2: CD001957.

258. Beyer W.E., Palache A.M., de Jong J.C., Osterhaus A.D. Coldadapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A metaanalysis. Vaccine 2002; 20: 1340-1353.

259. Gravenstein S., Drinka P., Duthie E.H. et al. Efficacy of an influenza hemagglutinindiphtheria toxoid conjugate vaccine in elderly nursing home subjects during an influenza outbreak. J. Am. Geriatr. Soc. 1994; 42: 245-251.

260. Keren G., Segev S., Morag A., Zakay-Rones Z., Barzilai A., Rubinstein E. Failure of influenza vaccination in the aged. J. Med. Virol. 1988; 25: 85-89.

261. Iorio A.M., Zei T., Neri M., Campitelli L., Castrucci M.R., Donatelli I. Immunization of elderly volunteers with the 1988-89 inactivated whole influenza vaccine: assessment of antibody responses by haemagglutination inhibition and single radial haemolysis tests. Eur. J. Epidemiol 1992; 8: 491-497.

262. Govaert T.M., Sprenger M.J., Dinant G.J., Aretz K., Masurel N., Knottnerus J.A. Immune response to influenza vaccination of elderly people. A randomized doubleblind placebocontrolled trial. Vaccine 1994; 12: 1185-1189.

263. Bernstein E., Kaye D., Abrutyn E., Gross P., Dorfman M., Murasko D.M. Immune response to influenza vaccination in a large healthy elderly population. Vaccine 1999; 17: 82-94.

264. Roos-Van Eijndhoven D.G., Cools H.J., Westendorp R.G., Cate-Hoek A.J., Knook D.L., Remarque E.J. Randomized controlled trial of seroresponses to double dose and booster influenza vaccination in frail elderly subjects. J. Med. Virol. 2001; 63: 293-298.

265. Margolis K.L., Nichol K.L., Poland G.A., Pluhar R.E. Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebocontrolled trial. J. A. M. A. 1990; 264: 1139-1141.

266. Govaert T.M., Dinant G.J., Aretz K., Masurel N., Sprenger M.J., Knottnerus J.A. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo con trolled trial. BMJ 1993; 307: 988-990.

267. Allsup S.J., Gosney M., Regan M., Haycox A., Fear S., Johnstone F.C. Side effects of influenza vaccination in healthy older people: a randomised singleblind placebo controlled trial. Gerontology 2001; 47: 311-314.

268. The safety of inactivated influenza vaccine in adults and children with asthma. N Engl. J. Med. 2001; 345: 1529-1536.

269. al-Mazrou A., Scheifele D.W., Soong T., Bjornson G. Comparison of adverse reactions to wholevirion and splitvirion influenza vaccines in hospital personnel. C. M. A. J. 1991; 145: 213-218.

270. Honkanen P.O., Keistinen T., Kivela S.L. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Arch. Intern. Med. 1996; 156: 205-208.

271. Nichol K.L., Mendelman P.M., Mallon K.P. et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. J. A. M. A. 1999; 282: 137-144.

272. Demicheli V., Rivetti D., Deeks J.J., Jefferson T.O. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev. 2000; 2: CD001269.

273. Govaert T.M., Thijs C.T., Masurel N., Sprenger M.J., Dinant G.J., Knottnerus J.A. The efficacy of influenza vaccination in elderly individuals. A randomized doubleblind placebo-controlled trial. JAMA 1994; 272: 1661-1665.

274. Gross P.A., Hermogenes A.W., Sacks H.S., Lau J., Levandowski R.A. The efficacy of influenza vaccine in elderly persons. A metaanalysis and review of the literature. Ann. Intern. Med. 1995; 123: 518-527.

275. Nichol K.L., Margolis K.L., Wuorenma J., Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N. Engl. J. Med. 1994; 331: 778-784.

276. Christenson B., Lundbergh P., Hedlund J., Ortqvist A. Effects of a largescale intervention with influenza and 23 valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet 2001; 357: 1008-1011.

277. Nordin J., Mullooly J., Poblete S. et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J. Infect. Dis. 2001; 184: 665-670.

278. Puig-Barbera J., Marquez-Calderon S., Masoliver-Fores A. et al. Reduction in hospital admissions for pneumonia in noninstitutionalised elderly people as a result of influenza vaccination: a casecontrol study in Spain. J. Epidemiol. Community Health 1997; 51: 526-530.

279. Crocetti E., Arniani S., Bordoni F., Maciocco G., Zappa M., Buiatti E. Effectiveness of influenza vaccination in the elderly in a community in Italy. Eur J. Epidemiol 2001; 17: 163-168.

280. Nichol K.L., Wuorenma J., Von Sternberg T. Benefits of influenza vaccination for low, intermediate, and high risk senior citizens. Arch. Intern. Med. 1998; 158: 1769-1776.

281. Hak E., Nordin J., Wei F. et al. Influence of highrisk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managedcare organizations. Clin. Infect. Dis. 2002; 35: 370-377.

282. Treanor J.J., Mattison H.R., Dumyati G. et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann. Intern. Med. 1992; 117: 625-633.

283. Monto A.S., Hornbuckle K., Ohmit S.E. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am. J. Epidemiol. 2001; 154: 155-160.

284. Deguchi Y., Takasugi Y., Tatara K. Efficacy of influenza vaccine in the elderly in welfare nursing homes: reduction in risks of mortality and morbidity during an influenza A (H3N2) epidemic. J. Med. Microbiol 2000; 49: 553-556.

285. Potter J., Stott D.J., Roberts M.A. et al. Influenza vaccination of health care workers in longtermcare hospitals reduces the mortality of elderly patients. J. Infect. Dis. 1997; 175: 1-6.

286. Carman W.F., Elder A.G., Wallace L.A. et al. Effects of influenza vaccination of healthcare workers on mortality of elderly people in longterm care: a randomised con trolled trial. Lancet 2000; 355: 93-97.

287. Bridges C.B., Thompson W.W., Meltzer M.I. et al. Effectiveness and costbenefit of influenza vaccination of healthy working adults: a randomized controlled trial. J. A. M. A. 2000; 284: 1655-1663.

288. Nichol K.L., Lind A., Margolis K.L. et al. The effectiveness of vaccination against influenza in healthy, working adults. N. Engl. J. Med. 1995; 333: 889-893.

289. Nichol K.L. Costbenefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch. Intern. Med. 2001; 161: 749-759.

290. Mullooly J.P., Bennett M.D., Hornbrook M.C. et al. Influenza vaccination programs for elderly persons: costeffectiveness in a health maintenance organization. Ann. Intern. Med. 1994; 121: 947-952.

291. Scott W.G., Scott H.M. Economic evaluation of vaccination against influenza in New Zealand. Pharmacoeconomics 1996; 9: 51-60.

292. Hak E., van Essen G.A., Buskens E., Stalman W., de Melker R.A. Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands. J. Epidemiol Community Health 1998; 52: 120-125.

293. Muennig P.A., Khan K. Costeffectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin. Infect. Dis. 2001; 33: 1879-1885.

294. Beyer W.E., de Bruijn I.A., Palache A.M., Westendorp R.G., Osterhaus A.D. Protection against influenza after annually repeated vaccination: a metaanalysis of serologic and field studies. Arch. Intern. Med. 1999; 159: 182-188.

295. Buxton J.A., Skowronski D.M., Ng H. et al. Influenza revaccination of elderly travellers: antibody response to single influenza vaccination and revaccination at 12 weeks. J. Infect. Dis. 2001; 184: 188-191.

296. Bridges C.B., Fukuda K., Cox N.J., Singleton J.A. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2001; 50: 1-44.

297. Lipsky B.A., Boyko E.J., Inui T.S., Koepsell T.D. Risk factors for acquiring pneumococcal infections. Arch. Intern. Med. 1986; 146: 2179-2185.

298. Nuorti J.P., Butler J.C., Farley M.M. et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial. Core Surveillance Team. N. Engl. J. Med. 2000; 342: 681-689. 299. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 1997; 46: 1-24.

299. Hedlund J.U., Kalin M.E., Ortqvist A.B., Henrichsen J. Antibody response to pneumococcal vaccine in middle aged and elderly patients recently treated for pneumonia. Arch. Intern. Med. 1994; 154: 1961-1965.

300. Sankilampi U., Honkanen P.O., Bloigu A., Herva E., Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J. Infect. Dis. 1996; 173: 387-393.

301. Carson P.J., Nichol K.L., O'Brien J., Hilo P., Janoff E.N. Immune function and vaccine responses in healthy advanced elderly patients. Arch. Intern. Med. 2000; 160: 2017-2024.

302. Rubins J.B., Puri A.K., Loch J. et al. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. J. Infect. Dis. 1998; 178: 431-440.

303. Rubins J.B., Alter M., Loch J., Janoff E.N. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect. Immun. 1999; 67: 5979-5984.

304. Romero-Steiner S., Musher D.M., Cetron M.S. et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin. Infect. Dis. 1999; 29: 281-288.

305. Sankilampi U., Honkanen P.O., Bloigu A., Leinonen M. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. J. Infect. Dis. 1997; 176: 1100-1104.

306. Konradsen H.B. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. Clin. Infect. Dis. 1995; 21: 616-620.

307. Hedlund J., Ortqvist A., Konradsen H.B., Kalin M. Recurrence of pneumonia in relation to the antibody response after pneumococcal vaccination in middleaged and elderly adults. Scand. J. Infect.Dis. 2000; 32: 281-286.

308. Powers D.C., Anderson E.L., Lottenbach K., Mink C.M. Reactogenicity and immunogenicity of a proteinconjugated pneumococcal oligosaccharide vaccine in older adults. J. Infect. Dis. 1996; 173: 1014-1018.

309. Shelly M.A., Jacoby H., Riley G.J., Graves B.T., Pichichero M., Treanor J.J. Comparison of pneumococcal polysaccharide and CRM197conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect. Immun. 1997; 65: 242-247.

310. Musher D.M., Groover J.E., Watson D.A., Rodriguez-Barradas M.C., Baughn R.E. IgG responses to protein conjugated pneumococcal capsular polysaccharides in per sons who are genetically incapable of responding to uncon jugated polysaccharides. Clin. Infect. Dis. 1998; 27: 1487-1490.

311. Jonsson S., Vidarsson G., Valdimarsson H., Schiffman G., Schneerson R., Jonsdottir I. Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine. Eur. Respir. J. 2002; 20: 813-818.

312. Jackson L.A., Benson P., Sneller V.P. et al. Safety of revaccination with pneumococcal polysaccharide vaccine. J. A. M. A. 1999; 281: 243-248.

313. Fine M.J., Smith M.A., Carson C.A. et al. Efficacy of pneumococcal vaccination in adults. A metaanalysis of randomized controlled trials. Arch. Intern. Med. 1994; 154: 2666-2677.

314. Hutchison B.G., Oxman A.D., Shannon H.S., Lloyd S., Altmayer C.A., Thomas K. Clinical effectiveness of pneumococcal vaccine. Metaanalysis. Can. Fam. Physician 1999; 45: 2381-2393.

315. Moore R.A., Wiffen P.J., Lipsky B.A. Are the pneumococcal polysaccharide vaccines effective? Metaanalysis of the prospective trials. BMC Fam. Pract. 2000; 1: 1.

316. Cornu C., Yzebe D., Leophonte P., Gaillat J., Boissel J.P., Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a metaanalysis of randomized trials. Vaccine 2001;19:4780-4790.

317. Watson L., Wilson B.J., Waugh N. Pneumococcal polysac charide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002; 20: 2166-2173.

318. Austrian R., Douglas R.M., Schiffman G. et al. Prevention of pneumococcal pneumonia by vaccination. Trans. Assoc. Am. Physicians 1976; 89: 184-194.

319. Smit P., Oberholzer D., Hayden-Smith S., Koornhof H.J., Hilleman M.R. Protective efficacy of pneumococcal polysaccharide vaccines. J. A. M. A. 1977; 238: 2613-2616.

320. Ortqvist A., Hedlund J., Burman L.A. et al. Randomised trial of 23valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middleaged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 1998; 351: 399-403.

321. Honkanen P.O., Keistinen T., Miettinen L. et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999; 17: 2493-2500.

322. Forrester H.L., Jahnigen D.W., LaForce F.M. Inefficacy of pneumococcal vaccine in a highrisk population. Am. J. Med. 1987; 83: 425-430.

323. Sims R.V., Steinmann W.C., McConville J.H., King L.R., Zwick W.C., Schwartz J.S. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann. Intern. Med. 1988; 108: 653-657.

324. Shapiro E.D,. Berg A.T., Austrian R. et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 1991; 325: 1453-1460.

325. Butler J.C., Breiman R.F., Campbell J.F., Lipman H.B., Broome C.V., Facklam R.R. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. J. A. M. A. 1993; 270: 1826-1831.

326. Farr B.M., Johnston B.L., Cobb D.K. et al. Preventing pneumococcal bacteremia in patients at risk. Results of amatched casecontrol study. Arch. Intern. Med. 1995; 155: 2336-2340.

327. Nichol K.L., Baken L., Wuorenma J., Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch. Intern. Med. 1999; 159: 2437-2442.

328. Vold P.P., Owens D.K. Costeffectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps. Clin. Infect. Dis. 2000; 30: 157-164.

329. Sisk J.E., Moskowitz A.J., Whang W. et al. Costeffectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278: 1333-1339.

330. Ament A., Baltussen R., Duru G. et al. Costeffectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin. Infect. Dis. 2000; 31: 444-450.